Novo Nordisk Share Price Already Reflects Plenty of Pessimism -- Market Talk

1039 GMT - Novo Nordisk has faced immense pricing and competitive pressures, but the share price has baked in more than its fair share of pessimism, AlphaValue analyst Abhishek Raval writes. Oral weight-loss options are likely to be the key vehicles of market expansion, and the Danish drug maker still maintains a massive lead with its Wegovy pill versus Eli Lilly's Foundayo, he says. Novo Nordisk's CagriSema, a next generation obesity/diabetes injection, is expected to launch in 2027, and potential game changer Zenagamtide, an obesity/diabetes drug in both pill and injection form, could launch in 2029. These should fortify Novo Nordisk's already dominant position in the coming years, Raval says. AlphaValue retains its buy rating on the stock and lifts its target price to 466 Danish kroner from 458 kroner. Shares rise 0.7% to 297.20 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

August 28, 2026 06:39 ET (10:39 GMT)